Skip to main content

Patricia Pozo Rosich

.

Institutions of which they are part

Head of group
Headache and Neurological Pain
Vall Hebron Institut de Recerca
Neurology
General Hospital

Patricia Pozo Rosich

Institutions of which they are part

Head of group
Headache and Neurological Pain
Vall Hebron Institut de Recerca
Neurology
General Hospital

.

.

Projects

Biomarcadores neuroinflamatorios en pacientes con migraña: prueba de concepto para el diagnóstico molecular de la enfermedad

IP: Marta Vila Pueyo
Collaborators: Laila Asskour, Patricia Pozo Rosich, Victor José Gallardo Lopez, Otilia Gliga
Funding agency: Fundación Eugenio Rodríguez Pascual
Funding: 24990
Reference: FERP-2023-MVP
Duration: 17/01/2024 - 16/01/2026

Digitalization in Migraine

IP: Patricia Pozo Rosich
Collaborators: Edoardo Caronna, Miriam Izquierdo Sans
Funding agency: Instituto de Salud Carlos III
Funding: 180000
Reference: JR23/00065
Duration: 01/01/2024 - 31/12/2027

X

IP: Patricia Pozo Rosich
Collaborators: Otilia Gliga, Miriam Izquierdo Sans
Funding agency: Instituto de Salud Carlos III
Funding: 89900
Reference: FI23/00149
Duration: 01/01/2024 - 31/12/2027

(PREDIMIGRAINE) Medicina de precisión para prevenir la cronificación de la migraña a través de la predicción de las crisis de dolor y de la respuesta al tratamiento con anticuerpos anti-CGRP utilizando estrategias multi-ómicas.

IP: Patricia Pozo Rosich
Collaborators: Alicia Alpuente Ruiz, Laila Asskour, Eulalia Gine Cipres, Victor José Gallardo Lopez, Edoardo Caronna
Funding agency: Instituto de Salud Carlos III
Funding: 369930
Reference: PMP22/00189
Duration: 01/01/2023 - 31/12/2025

Related news

Two international studies led by Vall d'Hebron recommend early administration of specific drugs to prevent migraine to achieve a better response to therapy.

On World Clinical Trials Day, we highlight some of the studies we have participated in that confirm the efficacy of new drugs, allowing their approval by regulatory agencies.

The study, conducted in more than 770 people, concludes that atogepant reduces the frequency of migraine attacks and the need to take medication.

Related professionals

Màrius Aguirre Canyadell

Màrius Aguirre Canyadell

Senior researcher
Musculoskeletal Tissue Engineering
Read more
Jorge Pamias Romero

Jorge Pamias Romero

New Technologies and Craniofacial Microsurgery
Read more
Luis Enrique Lara Moctezuma

Luis Enrique Lara Moctezuma

Kidney Physiopathology
Read more
Mayli Lung Suarez

Mayli Lung Suarez

Microbiology
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.